San Raffaele
Targeted therapy in Italy costs from $4,500 to $9,000 on average. Prices change based on the drug type, cancer stage, and city. In the US, similar procedures cost around $14,500 on average. Patients can find savings of around 53% compared to US prices. The cost usually includes the initial oncologist consultation and the medication administration.
Bookimed Expert Insight: Milan serves as Italy's primary hub for oncology. San Raffaele Hospital acts as a major research center. It is accredited by the Italian Ministry of Health (IRCCS). They pioneered the world's first stem cell therapy for ADA-SCID. Choosing Milan-based centers provides access to clinical trials. These trials can significantly reduce out-of-pocket costs for advanced therapies.
Why choose Italy for targeted therapy?
Access advanced Targeted therapy solutions in trusted clinics from $4,500.
| Italy | Turkey | Austria | |
| Targeted therapy | ≈ $4,500 | from $3,000 | ≈ $9,000 |
| Oncothermia | ≈ $3,600 | ≈ $2,400 | ≈ $2,400 |
| Lutetium-177 therapy | ≈ $9,500 | from $6,500 | ≈ $35,000 |
| Actinium-225 Therapy | ≈ $18,000 | from $23,000 | ≈ $55,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Targeted therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Targeted therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Targeted therapy journey.
Day 1: Arrival
Day 2: Pre-Operation Stage
Day 3: Targeted Therapy
Day 4: Post-Operation Stage
Week 1-2: Rehabilitation
Please note that each patient"s case is individual and can vary.
Dr. Fabio Ciceri heads the Hematology and Bone Marrow Transplantation Unit at San Raffaele Research Hospital. He is a primary investigator in clinical trials for cell and gene therapies. These trials treat hematological cancers, immune deficiencies, and neuromuscular disorders. Dr. Ciceri works at San Raffaele, the hospital that achieved the world's first stem cell therapy for ADA-SCID.
Written by Anna Shchur
When considering Targeted therapy, it’s important to understand the different techniques and which is best suited for you. Here’s a concise comparison of popular options:
Lutetium-177 therapy is a targeted radiotherapy utilizing the Lutetium-177 radioisotope to treat certain cancers effectively.
Genetic profiling in Italy involves a structured pathway where oncologists use next-generation sequencing (NGS) to identify actionable mutations. Pathologists obtain tumor tissue or liquid biopsies for analysis in accredited labs. A multidisciplinary molecular tumor board then reviews the results to match patients with personalized therapies or clinical trials.
Bookimed Expert Insight: Research centers like San Raffaele in Milan combine clinical care with active research. This allows patients to access advanced diagnostic tools like PET-MRI alongside standard molecular profiling. Facilities treating 12,000 cancer patients annually often provide faster access to broad biomarker panels than smaller regional hospitals.
Patient Consensus: Patients emphasize the importance of confirming turnaround times for molecular results before starting treatment. Most advise clarifying whether a test covers all driver mutations to avoid delays in finding the right drug.
Targeted cancer therapy in Italy requires European Medicines Agency (EMA) authorization followed by Italian Medicines Agency (AIFA) reimbursement approval. Italy uses digital registries and Health Technology Assessment (HTA) to monitor drug efficacy. Public access depends on biomarker testing and inclusion in the Servizio Sanitario Nazionale (SSN) system.
Bookimed Expert Insight: Speed of access depends on facility volume rather than just regulation. Large centers like San Raffaele in Milan treat 12,000 cancer patients annually. These institutions often provide faster access to second opinions and complex molecular testing. This infrastructure helps patients bypass administrative delays found in smaller regional clinics.
Patient Consensus: Access to treatment relies heavily on public health system enrollment and residency status. Verifying if a specific drug is already AIFA-reimbursed is essential before starting the clinical evaluation process.
Targeted therapies are fully covered by the Italian National Health Service (SSN) for eligible patients. The Italian Medicines Agency (AIFA) evaluates these drugs for safety and efficacy. Approved medicines fall under reimbursement categories Fascia A or Fascia H, meaning the public system covers 100% of the drug cost.
Bookimed Expert Insight: While public coverage is extensive, patients at centers like San Raffaele often use private consultations to speed up initial diagnosis. This clinic treats 12,000 cancer patients annually and uses advanced PET-MRI for precise molecular staging. Starting privately allows faster access to the public reimbursement pathway once the diagnosis is confirmed.
Patient Consensus: Patients note that the public system is financially generous but involves slow bureaucratic hurdles. To avoid delays, individuals often pay for private assessments before transitioning to public coverage for long-term drug administration.
Italy hosts globally recognized IRCCS Scientific Institutes for oncology, centering on precision medicine and molecular profiling. Key hubs include Milan's San Raffaele and Istituto Europeo di Oncologia, Rome's Regina Elena, and Naples' Fondazione Pascale. These centers lead in radioligand and molecular targeted therapies within JCI and Newsweek-ranked facilities.
Bookimed Expert Insight: Milan serves as the primary gateway for international oncology patients. San Raffaele alone handles 300,000 patients yearly and has completed over 1,000 bone marrow transplants. For complex cases, choosing a Milan-based IRCCS facility ensures access to the highest concentration of subspecialists and robotic technologies like the da Vinci system.
Patient Consensus: Patients recommend matching the facility to your specific tumor type rather than just general hospital reputation. Those seeking care in Milan or Rome emphasize asking clinics directly about molecular profiling availability before traveling.
International and non-resident patients can receive targeted therapy in Italy through the private healthcare sector or specialized international departments at major oncology centers. Access typically requires molecular profiling, previous pathology records, and an oncological evaluation at an IRCCS (Institutes for Scientific Research, Hospitalization and Health Care) facility.
Bookimed Expert Insight: Milan serves as a primary hub for complex oncology due to high-capacity centers like San Raffaele. This facility alone treats 12,000 cancer patients annually and holds IRCCS accreditation. For patients seeking radio-ligand subtypes, Lutetium-177 therapy costs significantly less than Actinium-225 treatments in Italian clinics.
Patient Consensus: Short-term visitors often face delays in the public system and should choose private routes for faster specialist access. Successful treatment depends on having all diagnostic records translated and confirming that the clinic provides English-speaking staff.